Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PM8002 plus standard chemotherapy as first-line treatment for unresectable malignant mesothelioma
CTR20221048Phase 2Active
- Sponsor
- Biotheus
- Start
- Aug 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of pumitamig in mesothelioma, sponsored by Biotheus. Started Aug 2022; status: active.
02
Drugs
pumitamig
03
Conditions
mesothelioma
Beyond the preview
Go deeper on CTR20221048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221048.